<DOC>
	<DOCNO>NCT01994642</DOCNO>
	<brief_summary>The objective study compare relative efficacy safety test formulation ciprofloxacin 0.3 % /dexamethasone 0.1 % sterile otic suspension ( Par ) already-marketed formulation CIPRODEXÂ® ( ciprofloxacin 0.3 % /dexamethasone 0.1 % ) sterile otic suspension ( Alcon ) treatment acute bacterial otitis medium child patent tympanostomy tube .</brief_summary>
	<brief_title>Bioequivalence Two Ciprofloxacin 0.3 % /Dexamethasone 0.1 % Sterile Otic Suspensions Otitis Media Children With Tympanostomy Tubes</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Male female age 6 months12 year age inclusive . 2 . Parent legal guardian sign informed consent form , meet criteria current FDA regulation . 3 . Based patient 's age , comprehension communication developmental skill provide assent participate appropriate format . 4 . Confirmed insertion patent tympanostomy tube ( ) infect ear ( ) . 5 . Clinical sign symptom consistent acute bacterial otitis medium least one ear score least 2 otorrhea use follow scale 0=none , 1=mild , 2=moderate , 3=severe , ( see Appendix A rating scale severity definition ) . 6 . Otorrhea present 21 day less . 7 . The presence infection confirm positive bacterial culture presence Staphylococcus aureus , Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis Pseudomonas aeruginosa . As result bacterial culture immediately know , patient meet inclusion/exclusion criterion may enrol study pending result bacterial culture . 1 . Tympanostomy tube placement occur within 3 day less screening visit . 2 . Tympanostomy tube contain silver oxide silver salt , Ttype tube . 3 . Signs symptoms otitis medium longer 21 day prior screen inclusion study . 4 . Since insertion tympanostomy tube ( ) , 1 previous episode otitis medium within previous 3 month 4 episode within previous 12 month . 5 . Provided therapeutic drug treatment current episode otitis medium within previous 14 day . 6 . Current previous history otologic surgery insertion/removal tympanostomy tube infect ear ( ) . 7 . Clinical diagnosis suggest current sign symptom cause acute bacterial otitis medium e.g . otitis externa 8 . Clinical diagnosis malignant otitis externa 9 . Mastoid cavity , stenosis , exostosis tumor either ear noninfectious disease either ear . 10 . Suspected concurrent fungal viral infection ( e.g . herpes simplex ) either ear . 11 . Dermatitis infect ear psoriasis seborrhea would complicate evaluation . 12 . Any known hypersensitivity ciprofloxacin carboxyquinolone derivative , dexamethasone corticosteroid ingredient formulation . 13 . Significant underlying disease diabetes , HIV immunocompromised condition receive therapy may cause patient immunocompromised . 14 . Significant history current evidence chronic infectious disease , system disorder , organ disorder medical condition Investigator 's opinion would place study patient undue risk participation could jeopardize integrity study evaluation . 15 . Investigator believe severity infection systemic antibiotic would prefer treatment option . 16 . Use systemic antibacterial product topical antibacterial product ear ( ) within 14 day screen study . 17 . Use systemic antiinflammatory product topical antiinflammatory product ear ( ) ( corticosteroids NSAIDs ) within 7 day screen study . 18 . Use topical otic medication affect ear within 7 day prior screen . 19 . Use astringent vinegar , alcohol medicate cleanse swab ear within 48 hour baseline bacterial culture swab . 20 . Receipt drug device part research study within 30 day prior dose . 21 . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>